Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on May 15, 2026 to 15 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee pursuant to Nasdaq Listing Rule 5635(c)(4).
The employees received a total of 5,308 restricted stock units, vesting in four equal annual installments, subject to continued employment.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MDGL
+0.71%
+0.71%Session close to close
In the May 22 session, MDGL gained 0.71%, reflecting a mild positive market reaction.
This announcement details routine inducement equity awards: 5,308 time-based RSUs granted to 15 new ...
Analysis
This announcement details routine inducement equity awards: 5,308 time-based RSUs granted to 15 new employees vesting over four years under Nasdaq Listing Rule 5635(c)(4). It continues a pattern of stock-based hiring in May 2026 following earlier grants. In context of strong recent Rezdiffra commercialization and pipeline expansion, investors may watch overall equity compensation levels, future hiring, and subsequent SEC filings to gauge cumulative dilution and governance practices.
Key Figures
New employees:15 employeesInducement RSUs:5,308 RSUsVesting schedule:4 installments+3 more
6 metrics
New employees15 employeesRecipients of inducement equity awards on May 15, 2026
Inducement RSUs5,308 RSUsAggregate time-based restricted stock units granted under 2025 Inducement Plan
Vesting schedule4 installmentsRSUs vest annually on first through fourth anniversaries of grant date
Current price$513.47Price prior to publication of inducement grant news
52-week range$265–$615MDGL 52-week low and high before this announcement
Market cap$12,040,356,800Equity value before this HR-related news
Arrowhead detailed financial terms of ARO‑PNPLA3 license to Madrigal.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent MDGL news often shows mixed alignment: strong fundamentals and strategic deals sometimes met with negative price reactions, while solid earnings saw a positive move.
Recent Company History
Over the last few weeks, Madrigal reported strong Rezdiffra commercialization with $311.3M in 1Q26 net sales and a 7.42% positive price reaction. It expanded its MASH pipeline via the ARO‑PNPLA3 license announced on May 5, 2026, though that news coincided with a -3.12% move. The company has also issued multiple inducement equity grants in May, including awards on May 1 and now May 15, reflecting ongoing hiring and stock-based compensation practices.
"approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
equity inducement awardsfinancial
"granted equity awards on May 15, 2026 to 15 new non-executive employees as equity inducement awards"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
restricted stock unitsfinancial
"The new employees received, in the aggregate, 5,308 time-based restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
time-based restricted stock unitsfinancial
"The new employees received, in the aggregate, 5,308 time-based restricted stock units."
Time-based restricted stock units are a form of employee compensation where individuals are granted company shares that are earned over a set period, often as a reward for staying with the company. These shares typically become fully owned and transferable only after passing specific time milestones, encouraging long-term commitment. For investors, they highlight a company's focus on employee retention and can influence future stock supply and company stability.
vestingfinancial
"All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 15, 2026 to 15 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 5,308 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact Tina Ventura, IR@madrigalpharma.com
Media Contact Christopher Frates, media@madrigalpharma.com
FAQ
What equity inducement awards did Madrigal Pharmaceuticals (MDGL) grant on May 15, 2026?
Madrigal Pharmaceuticals granted equity inducement awards totaling 5,308 restricted stock units to 15 new non-executive employees. According to Madrigal, these awards were issued under the 2025 Inducement Plan as a material inducement for employment and approved by the independent Compensation Committee.
How many restricted stock units did new Madrigal (MDGL) employees receive in May 2026?
New Madrigal employees received an aggregate of 5,308 time-based restricted stock units. According to Madrigal, these awards were granted under the 2025 Inducement Plan as inducement awards for 15 non-executive hires and will vest over four years, subject to continued employment.
How do the Madrigal Pharmaceuticals (MDGL) inducement awards vest for new employees?
The inducement restricted stock units vest in four equal annual installments. According to Madrigal, vesting occurs on each of the first through fourth anniversaries of the May 15, 2026 grant date and remains conditioned on each employee’s continued employment on the applicable vesting date.
Why did Madrigal Pharmaceuticals (MDGL) use Nasdaq Listing Rule 5635(c)(4) for these equity awards?
Madrigal used Nasdaq Listing Rule 5635(c)(4) to grant equity inducement awards to new employees. According to Madrigal, the rule allows equity grants as a material inducement to employment, with approval by the company’s independent Compensation Committee under its 2025 Inducement Plan.
Who is eligible for the May 2026 Madrigal (MDGL) inducement equity grants?
The May 2026 inducement equity grants were provided to 15 new non-executive employees. According to Madrigal, these employees received time-based restricted stock units as a material inducement to accept employment, with vesting dependent on continued service with the company over four years.
